The JavaScript innovation train is really picking up momentum lately, driven—as always—by the creativity of the JavaScript developer community. The emerging local-first SQL datastores crystalize ideas ...

Last year was characterized by fewer but larger venture capital financings for biotech, with 2025’s top 10 private rounds bringing in nearly $4 billion collectively. As venture markets rebounded ...

Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...

The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability. The WinterCG community group was recently ...

Nearly two years after Google DeepMind released AlphaFold 3, an updated version of its system for predicting protein structure that is geared towards drug discovery, its biopharmaceuticals spin-off, ...

Abstract: With the growing exchange of digital images in the Internet of Things (IoT), securing sensitive data, particularly medical images, has become critical. These images are essential for ...

According to The Rundown AI on X, Isomorphic Labs’ drug-design system more than doubled AlphaFold 3 performance on the hardest protein-ligand cases, signaling major gains in structure-based drug ...

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Deep Origin, the computational drug discovery company replacing guesswork with prediction in small molecule drug development, today ...

In the warm glow of the country’s jazz cafés, a subculture of vinyl aficionados is cultivating the kind of shared sensory experiences that our noisy world has forgotten. Legendary jazz club owners ...

Abstract: Graph representation learning is a fundamental research theme and can be generalized to benefit multiple downstream tasks from the node and link levels to the higher graph level. In practice ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.